Could a Brain-Boosting pill lift depression?

NCT ID NCT06235905

Completed Symptom relief Sponsor: Navitor Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested an experimental oral drug called SPN-820 in 40 adults with major depressive disorder. The drug aims to enhance a key brain signaling pathway (mTORC1) that may help improve mood. Researchers measured changes in depression scores over time to see if the drug is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPN-820 (also called NV-5138), an oral drug that boosts a brain signaling pathway
What this could lead to: If it works, this could point toward a new oral treatment for major depression that acts quickly on brain cell signaling.
What could go wrong: This was a small, early-phase trial with only 40 people and no placebo group, so results may not be reliable or apply to everyone. Depression symptoms can also improve on their own.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Viking Clinical Research

Temecula, California, 92591, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.